Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Monica Bertagnolli

Surgical Oncology · Harvard Medical School

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Todd Rosengart

Cardiac Surgery · BCM

View

Dr. Larry Kaiser

Thoracic Surgery · UPenn

View

Dr. Neri Cohen

Thoracic Surgery · XVIVO

View

Dr. Jad M Abdelsattar, M.D, FACS

Breast Surgical Onc · University of Oxford

View

Dr. Lauren Kopicky

Breast Surgical Onc · Cleveland Clinic

View

Dr. Jennifer Plichta

Breast Surgical Onc · Duke University

View

Dr. Sarah Blair

Breast Surgical Onc · UCSD

View

Dr. Karen Goodwin

Breast Surgical Onc · UCSF

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study.

    May 8, 2026DOI: 10.1245/s10434-026-19777-wJournal ArticleASO

    Written by: Beatrice J SunMaggie Y ZhouMarti LohmanRyan MokhtariAmanda SiyKristen CunananKristen N GanjooByrne Lee

    Find these authors on Roon

    BS
    Dr. Beatrice Sun
    Surgical Oncology · Stanford

    Summary

    BACKGROUND: Uterine leiomyosarcoma (uLMS) is an aggressive malignancy with high rates of peritoneal recurrence and poor survival. Although surgery for recurrent uLMS has shown encouraging results, addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is not well described. We evaluate safety and efficacy of cytoreductive surgery (CRS)-HIPEC with gemcitabine followed by systemic dacarbazine for recurrent uLMS.PATIENTS AND METHODS: This was an open-label, single-arm phase 2 study of patients with recurrent uLMS who underwent CRS-HIPEC at a single tertiary center (March 2021-May 2025). HIPEC was performed for 60 min with gemcitabine (1000 mg/m2), followed by six doses of adjuvant dacarbazine (1000 mg/m2). Primary study objective was 1-year progression-free survival. Secondary outcomes were adverse events, intraperitoneal recurrence, and quality of life.RESULTS: A total of 17 patients underwent CRS-HIPEC with gemcitabine for recurrent uLMS (median 55 years). Most patients had received prior systemic therapy (76%) and undergone at least two operations for uLMS (65%). Median PFS was 11 months, significantly longer than historical control of 3 months (p < 0.001). Median OS was not reached at follow up time over 3 years. The study was closed early due to slow accrual: at time of closure, two patients remained without evidence of disease recurrence. Median PCI was 7; all patients achieved CCR 0. There were no Clavien-Dindo grade 3 complications, and median postoperative stay was 7 days. Two patients experienced grade 4 toxicities (hypokalemia and neutropenia).CONCLUSIONS: CRS with gemcitabine HIPEC and adjuvant systemic chemotherapy is feasible without increased morbidity and has potential to improve outcomes and achieve long-term survival in patients with recurrent uLMS.
    BSDr. Beatrice Sun

    Dr. Beatrice Sun

    Surgery · Surgical Oncology
    Stanford Medicine
    beatrice